Recruiting studies: Gastro Esophageal Junction Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860 Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818 Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06572319 Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07427992 A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced
NA · 1 location(s) · Fudan University · NCT06158919 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187 SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07464756 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastr
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06423885 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531 First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373 A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Ga
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07118527 KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT05427383 Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Phase 2 · 3 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT05687357 Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Phase 2 · 1 location(s) · Dallas VA Medical Center · NCT04018872 A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Phase 1 · 10 location(s) · Epkin · NCT06789172 Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06761846 A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06774222 QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305 A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-pos
Phase 1/Phase 2 · 30 location(s) · Antengene Biologics Limited · NCT07327229 Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Phase 2 · 2 location(s) · Weill Medical College of Cornell University · NCT06340711 Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
Phase 2 · 3 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07689851 Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07551362 Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Phase N/A · 1 location(s) · Fudan University · NCT07389876 XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05494060 A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299 XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/Phase 2 · 2 location(s) · West China Hospital · NCT06742411 A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocar
Phase N/A · 76 location(s) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT05993234 Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036 Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06808971

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →